The ACOSOG Z9001 trial showed that 1‐year adjuvant IM enhances RFS but not OS in high‐risk, KIT‐positive GIST patients post resection, leading to national guidelines endorsing a 1‐year regimen [12]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.